Interleukin-11 rDNA

Interleukin-1ra rDNA

Interleukin 6 IL 6 Receptor IL 6R

Although the causes of rheumatoid arthritis are not fully understood, constitutive overproduction of interleukin-6 (IL-6), a multifunctional cytokine that regulates immune response, inflammatory react...

Interleukin IL-6 receptor Mab rDNA

Interleukin-1 trap rDNA

Cytheris announces CYT107 orphan drug designation in Europe for the treatment of Progressive Multifocal Leucoencephalopathy (PML)

Cytheris SA announced that the European Commission has granted an orphan designation for Cytheris' CYT017, glycosylated recombinant human interleukin-7 (glycosylated r-h-IL7), for the treatment of Pro...

Cytheris announces US Orphan Drug Designation for CYT107 for Progressive Multifocal Leucoencephalopathy

Cytheris SA announced that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designation for Cytheris’ CYT017, glycosylated recombinant human interleukin-7 (glycosylated r-h-IL7),...

Cytheris Announces Publication in Blood Demonstrating CYT107 Reverses Lymphopenia and Increases Virus-Specific Immunity Post Stem Cell Transplantation

Data strongly supports development of CYT107 for treatment of Progressive Multifocal Leukoencephalopathy (PML) in lymphopenic patients Paris, October 9, 2012 - Cytheris SA, a privately held clinical-s...

Cytheris: Encouraging responses and orphan drug designation in Europe for CYT107 for the treatment of PML

In this episode of PharmaTelevision News Review, filmed at #BIO2012 Convention in Boston, Fintan Walton talks to Damian Marron, CEO of Cytheris about encouraging responses and orphan drug designatio...

Progressive Multifocal Leucoencephalopathy (PML) Treatment Receives US Orphan Drug Designation

Cytheris SA, a clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases, has announced that the US Food and Drug Administration (FDA) has granted an Orphan Drug Designa...

Cytheris to present interim data from ECLIPSE II Hepatitis C multicenter study at AASLD annual meeting

Paris, October 26, 2011 – Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from...

Increased production of interleukin-21, but not interleukin-17A, in the small intestine characterizes pediatric celiac disease

CEO of Interleukin leaves post

Lewis Bender has stepped down as CEO of Interleukin Genetics, a maker of genetic tests for specific chronic diseases, effecti -More- 

Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival.

Although great effort is being expended in the development of cancer immunotherapies, it is surprising that global lymphopenia and its various dimensions are not being systematically assessed in cance...

Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.

Type 17 helper T cells have been suggested to play a pathological role in psoriasis. They secrete several proinflammatory cytokines, including interleukin-17A (also known as interleukin-17). We evalua...

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

Stimulating an immune response against cancer with the use of vaccines remains a challenge. We hypothesized that combining a melanoma vaccine with interleukin-2, an immune activating agent, could impr...

Interleukin 6 and interleukin 8 play important roles in systemic inflammatory response syndrome of meconium peritonitis.

PURPOSE: Meconium peritonitis is caused by an intestinal perforation that may occur in the fetus, followed by severe chemical peritonitis, resulting in high morbidity....

Kidney injury and alterations of inflammatory cytokine expressions in mice following long-term exposure to cerium chloride.

It has been demonstrated that the organic damages of animals can be caused by exposure to lanthanide oxides or compounds. However, the molecular mechanism of CeCl3 -induced kidney injury remains uncle...